Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation

Ten-eleven translocation (TET) methylcytosine dioxygenases are part of the epigenetic regulatory machinery that erases DNA methylation. Aberrant TET activities are frequently found in hematopoietic malignancies, where loss of TET2 function leads to DNA hypermethylation. A comprehensive understanding of the biological role of TETs is essential to elucidate disease pathogenesis and identify novel therapeutic strategies. We present a robust pipeline integrating protein X-ray crystallography, molecular modeling, and pharmacophore analysis to advance the current TET inhibitor development. In addition, we have synthesized and evaluated a series of 8-hydroxyquinoline (8-HQ) derivatives, demonstrating their potential as chemical tools to explore TET function further. These findings lay the groundwork for a TET-centered therapeutic approach.

Authors

Institutions

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2025-04-08
DOI
https://doi.org/10.1021/acsmedchemlett.5c00042
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation

Suzanne Willems, Tom Schulz, Sonja Sievers, Janina Niggenaber et al.
ACS Medicinal Chemistry Letters
Epigenetics and DNA Methylation
article

Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation

Suzanne Willems, Tom Schulz, Sonja Sievers, Janina Niggenaber, Daniel Summerer, Daniel Rauh, Matthias Philipp Müller, Jörn Weisner, Tzu‐Chen Lin, Lejla Maksumic
article en

Abstract

Ten-eleven translocation (TET) methylcytosine dioxygenases are part of the epigenetic regulatory machinery that erases DNA methylation. Aberrant TET activities are frequently found in hematopoietic malignancies, where loss of TET2 function leads to DNA hypermethylation. A comprehensive understanding of the biological role of TETs is essential to elucidate disease pathogenesis and identify novel therapeutic strategies. We present a robust pipeline integrating protein X-ray crystallography, molecular modeling, and pharmacophore analysis to advance the current TET inhibitor development. In addition, we have synthesized and evaluated a series of 8-hydroxyquinoline (8-HQ) derivatives, demonstrating their potential as chemical tools to explore TET function further. These findings lay the groundwork for a TET-centered therapeutic approach.

ACS Medicinal Chemistry LettersVol. 16(5)
TU Dortmund University (DE), Max Planck Institute of Molecular Physiology (DE)
Deutsche Forschungsgemeinschaft, European Synchrotron Radiation Facility, Bundesministerium für Bildung und Forschung, Deutsche Krebshilfe, Mercator Research Center Ruhr, Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, European Regional Development Fund
Openalex Percentile: Top 94%
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Advancing TET Inhibitor Development: From Structural Insights to Biological Evaluation — Suzanne Willems, Tom Schulz, et al. · ACS Medicinal Chemistry Letters (2025) | TGRS Research Map | TGRS